Bill > S724

This bill addresses healthcare access and affordability through three key provisions: First, it repeals two sections of a 2012 law. Second, the bill mandates that health insurance carriers and pharmacy benefit managers (PBMs) pass at least 80% of estimated drug rebates to insured patients by reducing their out-of-pocket costs at the point of sale, while protecting the confidentiality of specific rebate details. This aims to make prescription drugs more affordable by ensuring patients benefit from negotiated price concessions. Third, the bill requires the Health Policy Commission and the Secretary of Health and Human Services to conduct a comprehensive analysis of cell and gene therapies, focusing on potential access barriers for MassHealth (Massachusetts' Medicaid program) beneficiaries and vulnerable populations between 2027 and 2037. The analysis must project the number of expected therapies, assess current reimbursement frameworks, identify potential access barriers, and propose policy solutions to ensure equitable access to these advanced medical treatments. The findings will be reported by July 30, 2028, and will involve consultation with key healthcare and biotechnology stakeholders.

Business and Industry, Health and Social Services

https://malegislature.gov/Bills/194/S724